Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls

•A review of non-approved/discontinued drugs relevant for doping controls is presented.•Substances arguably affecting skeletal muscle and oxygen transport capacities are discussed.•Analytical aspects of low and high molecular mass compounds in the light of modern sports drug testing programs are out...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical and biomedical analysis 2014-12, Vol.101, p.66-83
Main Authors: Thevis, Mario, Schänzer, Wilhelm
Format: Article
Language:English
Subjects:
Anti-myostatin antibody
Doping
Doping in Sports - prevention & control
Drug Approval - methods
Emerging drugs
Humans
Mass spectrometry
Performance-Enhancing Substances - chemistry
Pharmaceutical Preparations - chemistry
Sport
Stamulumab
Substance Abuse Detection - methods
Tandem Mass Spectrometry - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•A review of non-approved/discontinued drugs relevant for doping controls is presented.•Substances arguably affecting skeletal muscle and oxygen transport capacities are discussed.•Analytical aspects of low and high molecular mass compounds in the light of modern sports drug testing programs are outlined.•Relevant representatives of drug classes and mass spectral data are summarized. The number and diversity of potentially performance-enhancing substances is continuously growing, fueled by new pharmaceutical developments but also by the inventiveness and, at the same time, unscrupulousness of black-market (designer) drug producers and providers. In terms of sports drug testing, this situation necessitates reactive as well as proactive research and expansion of the analytical armamentarium to ensure timely, adequate, and comprehensive doping controls. This review summarizes literature published over the past 5 years on new drug entities, discontinued therapeutics, and ‘tailored’ compounds classified as doping agents according to the regulations of the World Anti-Doping Agency, with particular attention to analytical strategies enabling their detection in human blood or urine. Among these compounds, low- and high-molecular mass substances of peptidic (e.g. modified insulin-like growth factor-1, TB-500, hematide/peginesatide, growth hormone releasing peptides, AOD-9604, etc.) and non-peptidic (selective androgen receptor modulators, hypoxia-inducible factor stabilizers, siRNA, S-107 and ARM036/aladorian, etc.) as well as inorganic (cobalt) nature are considered and discussed in terms of specific requirements originating from physicochemical properties, concentration levels, metabolism, and their amenability for chromatographic-mass spectrometric or alternative detection methods.
ISSN:0731-7085
1873-264X
DOI:10.1016/j.jpba.2014.05.020